Tags

Type your tag names separated by a space and hit enter

Venous thromboembolism in cancer patients: Still looking for answers.
Exp Ther Med 2019; 18(6):5026-5032ET

Abstract

Patients with cancer-associated venous thromboembolism (VTE) represent a real challenge in clinical practice. Patients with cancer have a greater risk both of VTE and bleeding. There are only a few studies regarding the therapeutic approach of VTE in patients with cancer, especially after cancer surgery, and on thromboprophylaxis during chemotherapy. Many of the anticoagulation therapy recommendations for cancer patients are extrapolated from trials that are not conducted in cancer cohorts. It is essential to assess the efficacy and safety of VTE prophylaxis in this particular subgroup, which bears higher risks both of VTE recurrence and major hemorrhagic events. The introduction of direct oral anticoagulants in everyday practice represented a major evolution of the anticoagulant treatment. Direct anticoagulants could represent a more appealing alternative to low-molecular-weight heparin in paraneoplastic venous thrombosis, due to the patient comfort, easy administration of the drug and emerging studies that prove similar efficacy and safety as the standard treatment. However, there is limited data on the treatment with direct oral anticoagulants in patients with paraneoplastic venous thromboembolism.

Authors+Show Affiliations

Internal Medicine Department, Clinical Emergency Hospital of Bucharest, 014461 Bucharest, Romania.Urology Department, Emergency University Central Military Hospital, 010825 Bucharest, Romania. Academy of Romanian Scientists, Bucharest 030167, Romania. University of Medicine and Pharmacy 'Carol Davila', 050474 Bucharest, Romania.Urology Department, Emergency University Central Military Hospital, 010825 Bucharest, Romania. University of Medicine and Pharmacy 'Carol Davila', 050474 Bucharest, Romania.University of Medicine and Pharmacy 'Carol Davila', 050474 Bucharest, Romania. Urology Department, 'Prof. Th. Burghele' Clinical Hospital, 050652 Bucharest, Romania.Urology Department, Emergency University Central Military Hospital, 010825 Bucharest, Romania. Academy of Romanian Scientists, Bucharest 030167, Romania. University of Medicine and Pharmacy 'Carol Davila', 050474 Bucharest, Romania.University of Medicine and Pharmacy 'Carol Davila', 050474 Bucharest, Romania. Surgery Department, 'St. Pantelimon' Clinical Emergency Hospital, 021659 Bucharest, Romania.University of Medicine and Pharmacy 'Carol Davila', 050474 Bucharest, Romania.Internal Medicine Department, Clinical Emergency Hospital of Bucharest, 014461 Bucharest, Romania. University of Medicine and Pharmacy 'Carol Davila', 050474 Bucharest, Romania.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

31819767

Citation

Iorga, Roua Anamaria, et al. "Venous Thromboembolism in Cancer Patients: Still Looking for Answers." Experimental and Therapeutic Medicine, vol. 18, no. 6, 2019, pp. 5026-5032.
Iorga RA, Bratu OG, Marcu RD, et al. Venous thromboembolism in cancer patients: Still looking for answers. Exp Ther Med. 2019;18(6):5026-5032.
Iorga, R. A., Bratu, O. G., Marcu, R. D., Constantin, T., Mischianu, D. L. D., Socea, B., ... Diaconu, C. C. (2019). Venous thromboembolism in cancer patients: Still looking for answers. Experimental and Therapeutic Medicine, 18(6), pp. 5026-5032. doi:10.3892/etm.2019.8019.
Iorga RA, et al. Venous Thromboembolism in Cancer Patients: Still Looking for Answers. Exp Ther Med. 2019;18(6):5026-5032. PubMed PMID: 31819767.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Venous thromboembolism in cancer patients: Still looking for answers. AU - Iorga,Roua Anamaria, AU - Bratu,Ovidiu Gabriel, AU - Marcu,Radu Dragos, AU - Constantin,Traian, AU - Mischianu,Dan Liviu Dorel, AU - Socea,Bogdan, AU - Gaman,Mihnea-Alexandru, AU - Diaconu,Camelia Cristina, Y1 - 2019/09/18/ PY - 2019/07/22/received PY - 2019/08/21/accepted PY - 2019/12/11/entrez PY - 2019/12/11/pubmed PY - 2019/12/11/medline KW - cancer KW - direct oral anticoagulants KW - heparin KW - paraneoplastic KW - venous thromboembolism SP - 5026 EP - 5032 JF - Experimental and therapeutic medicine JO - Exp Ther Med VL - 18 IS - 6 N2 - Patients with cancer-associated venous thromboembolism (VTE) represent a real challenge in clinical practice. Patients with cancer have a greater risk both of VTE and bleeding. There are only a few studies regarding the therapeutic approach of VTE in patients with cancer, especially after cancer surgery, and on thromboprophylaxis during chemotherapy. Many of the anticoagulation therapy recommendations for cancer patients are extrapolated from trials that are not conducted in cancer cohorts. It is essential to assess the efficacy and safety of VTE prophylaxis in this particular subgroup, which bears higher risks both of VTE recurrence and major hemorrhagic events. The introduction of direct oral anticoagulants in everyday practice represented a major evolution of the anticoagulant treatment. Direct anticoagulants could represent a more appealing alternative to low-molecular-weight heparin in paraneoplastic venous thrombosis, due to the patient comfort, easy administration of the drug and emerging studies that prove similar efficacy and safety as the standard treatment. However, there is limited data on the treatment with direct oral anticoagulants in patients with paraneoplastic venous thromboembolism. SN - 1792-0981 UR - https://www.unboundmedicine.com/medline/citation/31819767/Venous_thromboembolism_in_cancer_patients:_Still_looking_for_answers L2 - https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/31819767/ DB - PRIME DP - Unbound Medicine ER -